Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Article in Journal of Oncology Pharmacy Practice (April 2024)
The most recent citing publications are shown below. View all 74 publications that cite this research output on Dimensions.
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer
Article in Oncogene (March 2024)
Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
Article in Frontiers in Oncology (February 2024)